Skip to main content

Table 1 Demographic and clinical characteristics of patients with SSc and control subjects

From: Inhibition of angiogenesis by platelets in systemic sclerosis patients

Characteristic Patients (n = 30) Control subjects (n = 12)
Female sex, % 96.6 91.6
Age, yr, mean (SD) 51.3 (16.8) 41.9 (14.7)
Disease duration, mo, mean (SD) 128.5 (18.4)  
Disease subset   
 Diffuse systemic sclerosis, % 17.2  
 Limited systemic sclerosis, % 82.8  
ANA positivity (>1:80), % 100 0
 Centromere, % 71.4  
 Nucleolar, % 3.7  
 Other, % 25  
Anti-Scl-70 16.1  
Anti-RNA polymerase III 6.7  
ESR, mm/h, mean (SD) 32.7 (33.6)  
Hemoglobin, g/dl, mean (SD) 12.5 (1.2)  
WBC, n/μl, mean (SD) 7288.21 (2836.6)  
Platelets, 109/L, mean (SD) 245 (65)  
CRP, mg/L, mean (SD) 0.47 (0.5)  
Ultrasensitive CRP μg/ml, mean (SD) 12.24 (28.2) 5.08 (1.0)
Complement component C3, mg/dl, mean (SD) 104.42 (20.2)  
Complement component C4, mg/dl, mean (SD) 17.42 (5.79)  
Raynaud’s phenomenon, % 89.66  
Gastrointestinal symptoms, % 75.0  
Digital ulcers, % 31.3  
Calcinosis, % 17.2  
Lung fibrosis, % 23.3  
Pulmonary arterial hypertension, % 13.3  
Current therapies, %   
 Mycophenolate mofetil 16.7  
 Methotrexate 26.7  
 Cyclophosphamide 6.7  
 Prednisone 18.7  
  1. ANA antinuclear antibodies, CRP C-reactive protein, ESR erythrocyte sedimentation rate, IQR interquartile range, SD standard deviation, WBC white blood cell count